201 related articles for article (PubMed ID: 28447489)
1. Forodesine in the treatment of cutaneous T-cell lymphoma.
Lewis DJ; Duvic M
Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
[TBL] [Abstract][Full Text] [Related]
2. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
Maruyama D; Tsukasaki K; Uchida T; Maeda Y; Shibayama H; Nagai H; Kurosawa M; Suehiro Y; Hatake K; Ando K; Yoshida I; Hidaka M; Murayama T; Okitsu Y; Tsukamoto N; Taniwaki M; Suzumiya J; Tamura K; Yamauchi T; Ueda R; Tobinai K
Ann Hematol; 2019 Jan; 98(1):131-142. PubMed ID: 29974231
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies.
Ogura M; Tsukasaki K; Nagai H; Uchida T; Oyama T; Suzuki T; Taguchi J; Maruyama D; Hotta T; Tobinai K
Cancer Sci; 2012 Jul; 103(7):1290-5. PubMed ID: 22448814
[TBL] [Abstract][Full Text] [Related]
5. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
6. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
8. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
9. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
10. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
11. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
12. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
13. New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ
Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides: pathophysiology and emerging therapies.
Duvic M; Foss FM
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
[TBL] [Abstract][Full Text] [Related]
15. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
16. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
17. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
18. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
19. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
20. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
